What Orexigen Is Saying -- and Not Saying
What Orexigen Is Saying -- and Not Saying Motley Fool
View Article3 Horrendous Health-Care Stocks This Week
3 Horrendous Health-Care Stocks This Week Motley Fool
View ArticleAre Allergan and Orexigen Warming Up?
Are Allergan and Orexigen Warming Up? Motley Fool
View Article3 Biopharmaceuticals Weighed By Uncertainty
3 Biopharmaceuticals Weighed By Uncertainty Seeking Alpha
View ArticleOrexigen: Is Contrave The Long-Term Winner In The Anti-Obesity Drug Wars?
Orexigen: Is Contrave The Long-Term Winner In The Anti-Obesity Drug Wars? Seeking Alpha
View ArticleKey Dates For Arena And Orexigen Investors
Key Dates For Arena And Orexigen Investors Seeking Alpha
View ArticleThe Biggest Loser in the Obesity Drug Market
The Biggest Loser in the Obesity Drug Market Motley Fool
View ArticleThe Obesity Epidemic: EnteroMedics' New Treatment Approach
The Obesity Epidemic: EnteroMedics' New Treatment Approach Seeking Alpha
View ArticleSix Things to Watch at Biotech CEO Conference
Six Things to Watch at Biotech CEO Conference Minyanville
View ArticleWill There Ever Be an Obesity Drug Blockbuster?
Will There Ever Be an Obesity Drug Blockbuster? Motley Fool
View Article3 Humongous Health-Care Stocks This Week
3 Humongous Health-Care Stocks This Week Motley Fool
View ArticleOrexigen Therapeutics Reports Financial Results for the Fourth Quarter and...
Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012 Yahoo
View ArticleShould Anti-Obesity Drug Company Stocks Trade In Tandem?
Should Anti-Obesity Drug Company Stocks Trade In Tandem? Seeking Alpha
View ArticleHow Doctors Actually Diagnose Obesity
How Doctors Actually Diagnose Obesity Motley Fool
View ArticleVivus Gets Restrictions Loosened
Vivus Gets Restrictions Loosened; Will Be Available in Retail Pharmacies Later This Year Seeking Alpha
View ArticleArena Faces A Convergence Of DEA And European Decisions
Arena Faces A Convergence Of DEA And European Decisions Seeking Alpha
View ArticleExciting Catalysts Approaching for This Bet
Exciting Catalysts Approaching for This Bet Motley Fool
View Article
